Loading...
Market
Will Centessa ($CNTA) announce a partnership or acquisition related to ORX750 by March 31, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official press release from Centessa Pharmaceuticals or news reports from reputable sources
Story
Centessa ($CNTA) Hits Three-Year High on Positive Phase 1 Data for ORX750
Sep 10, 2024, 02:21 PM
Centessa Pharmaceuticals ($CNTA) has announced positive interim Phase 1 clinical data for its novel Orexin Receptor 2 (OX2R) agonist, ORX750. The study involved acutely sleep-deprived healthy volunteers and has shown promising results. This development has propelled Centessa's stock to a three-year high, highlighting a significant $5 billion opportunity in the narcolepsy market. The milestone was celebrated by the Centessa team, including Mario Accardi.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Partnership with a pharmaceutical company • 33%
Acquisition by another company • 33%
No partnership or acquisition • 34%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
